Evidence map›Paper›PMID 41121472›Full record

ReviewCurrent pharmaceutical design2026

Otic Drug Delivery Systems: Current and Future Perspectives.

Evren Algın Yapar, İmren Esentürk-Güzel, Merve Nur Özdemir, Lüceyn Abdo

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Evren Algın YaparDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Türkiye.ORCID 0000-0002-6504-4608
İmren Esentürk-GüzelDepartment of Pharmaceutical Technology, Hamidiye Faculty of Pharmacy, University of Health Sciences, Istanbul, Türkiye.
Merve Nur ÖzdemirDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Türkiye.
Lüceyn AbdoHamidiye Institute of Health Sciences, University of Health Sciences, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many people worldwide suffer from various ear diseases, and their treatments are still challenging. The tympanic, round, and oval windows, and the blood-perilymph barrier are the three main physical obstacles to drug delivery. Conventional methods, such as oral administration or injections, often fail to overcome these obstacles. However, local drug delivery systems present a potential solution by reducing side effects and allowing higher drug concentrations to reach the inner ear. Numerous drug delivery techniques and patents have been evaluated in clinical and research settings in recent years. Even though otic drug delivery has evolved, there are still a number of issues, and further study is required to maximize these therapeutic modalities for clinical use. This review summarizes various local drug delivery techniques. Current barriers in otic drug delivery are highlighted, as well as innovative systems for future clinical applications.

Indexed as

Drug Delivery SystemsEar DiseasesAnimalsHumansclinical trialsEar diseaseML driven drugnanomedicineotic drug deliverypatents

Identifiers

PMID41121472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.